Provisional programme


Sunday 6 March 2011
 

 

18.00-19.00 Buffet dinner
 
19.00-20.50 Short position statements 
Chairs: Guy Goodwin, United Kingdom
Philippe Cupers, Belgium

 

19.00 Welcome and introduction 
Guy Goodwin, United Kingdom
  
19.05 The current and future size and burden of brain disorders in Europe
Hans-Ulrich Wittchen, Germany 
 
19.20 Health economics of brain disorders in Europe 
Bengt Jönsson, Sweden
  
19.35 The current position of the Pharmaceutical  Industry-1
Atul C. Pande, GSK
     
19.50 The current position of the Pharmaceutical Industry- 2
Anders G. Pedersen, Lundbeck
 
20.05 The current position of the Pharmaceutical Industry- 3
Jeffrey S. Nye, Johnson&Johnson
  
20.20 The current position of the European Union-1
  
20.35 The current position of the European Union-2
Philippe Cupers, EU DG Research, Innovation and Science
     
20.50-21.30

General discussion and scene-setting for tomorrow

21.30 Dessert and drinks
   

 


Monday 7 March 2011
 

 

08.30-10.30 The scientific dimension
Chairs: Patrice Boyer, France 
David Nutt, United Kingdom

 

08.30-08.35 Introduction
David Nutt, United Kingdom
   
08.35 Rationalising the approach to drug discovery for brain disorders
Sven Schellberg, Switzerland
08.50 Discussion  
 
09.00 Rationalising barriers to clinical research
Adam Cohen, The Netherlands     
09.15 Discussion 
 
09.25 Is there a role for academic networks?
Celso Arango, Spain  
09.40 Discussion
   
09.50 Sharing costs: Is the Innovative Medicines Initiative (IMI) a model for clinical
development?
Shitij Kapur, United Kingdom
10.05

Discussion

10.15 General discussion
   
10.30 Break
   

 

11.00-11.45 Regulatory challenges: past, present and future
Chairs: Christine Gispen-de Wied, EMA
David Nutt, United Kingdom

 

11.00 Introduction
Christine Gispen-de Wied, EMA   
 
11.05 EMA responsibilities and possibilities
Maria Isaac, EMA
11.20 Discussion 
  
11.30 Optimising guidelines 
Barbara van Zwieten-Boot, EMA   
11.45 Discussion 
  

 

11.55-12.25 The NIH approach to discovering new treatments
Chair: Joseph Zohar, Israel

 

11.55 Introduction
Joseph Zohar, Israel   
 
12.00 The NIH approach to discovering new treatments
Thomas R.  Insel, USA 
12.15 Discussion  
12.25 Lunch  
 

 

13.30-16.00 The future of CNS drug research in Europe
Chairs: Guy Goodwin, United Kingdom 
Thomas Lönngren, past-ED EMA
Facilitator: David Nutt, United Kingdom

 

13.30 General discussion and brainstorming of possible solutions 
   
15.30 Agreeing the ways forward and future meetings 
 
16.00 Closure of the meeting
   
     
 

Related pages / downloads

 

Participants